Moderna today reported that that the bivalent (two-strain) mRNA vaccine it developed against Omicron showed a strong neutralizing antibody response against the Omicron BA.4 and BA.5 subvariants and that it will seek regulatory approval in the coming weeks.

Moderna’s bivalent vaccine contains its original vaccine plus a strain that targets Omicron and its subvariants.

Source: Moderna 2-strain booster shows strong subvariant antibody response | CIDRAP